BioPharmX Priced, NYSE American: BPMX

Developing therapies for fibrocystic breasts and acne.

Industry: Health Care

Latest Trade: $0.29 -0.01 (-4.7%)

First Day Return: -3.6%

Return from IPO: -89.1%

Industry: Health Care

We are a specialty pharmaceutical company focused on utilizing our proprietary drug delivery technologies to develop and commercialize novel prescription and over-the-counter, or OTC, products that address large markets in dermatology and women's health. Our objective is to develop products that treat health or age-related conditions that: are not presently being addressed or treated or are currently treated with drug therapies or drug delivery approaches that are sub-optimal. Our strategy is designed to bring new products to market by identifying optimal delivery mechanisms and/or alternative applications for FDA approved active pharmaceutical ingredient and biological materials, while, in appropriate circumstances, reducing the time, cost and risk typically associated with new product development by repurposing drugs with demonstrated safety profiles and, when applicable, taking advantage of the regulatory approval pathway under the FDC Act. We believe these approaches may reduce drug development risk and could reduce the time and resources we spend during development. Our current platform technologies include innovative delivery mechanisms for antibiotics, biological materials and molecular iodine.
more less
IPO News for BioPharmX
more
IPO Data
IPO File Date 04/09/2015
Offer Price $2.75
Price Range $2.75 - $3.25
Offer Shares (mm) 3.6
Deal Size ($mm) $10
IPO Data
IPO Date 06/24/2015
Offer Price $2.75
Price Range $2.75 - $3.25
Offer Shares (mm) 3.6
Deal Size ($mm) $10
Underwriters
more
Company Data
Headquarters Menlo Park, CA
Founded 2010
Employees 24
Website www.BioPharmX.com